Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Josianne Nitcheu
Observed names:
J Nitcheu,
J. Nitcheu,
Josiane Nitcheu
Institution:
Abivax (France)
Observed institutions:
Inserm,
Queen Mary University of London,
Cancer Research UK,
Pitié-Salpêtrière Hospital,
Abivax (France),
Immuno-biologie cellulaire et moléculaire des infections parasitaires
show all 6
ORCID:
0000-0003-2713-6605
Observed ORCID:
0000-0003-2713-6605
OpenAlex ID:
A5045408648
Works
27
Awards
1
Perforin-Dependent Brain-Infiltrating Cytotoxic CD8+ T Lymphocytes Mediate Experimental Cerebral Malaria Pathogenesis
2003
·
Josianne Nitcheu
, Olivia Bonduelle
, et al.
·
The Journal of Immunology
·
295
PDF
Bacterial gene therapy strategies
2005
·
Georges Vassaux
, Josianne Nitcheu
, et al.
·
The Journal of Pathology
·
126
PDF
ABX464 (obefazimod) for moderate-to-severe, active ulcerative colitis: a phase 2b, double-blind, randomised, placebo-controlled induction trial and 48 week, open-label extension
2022
·
Severine Vermeire
, Bruce E Sands
, et al.
·
The Lancet. Gastroenterology & hepatology
·
76
Cerebral malaria and immunogenetics
2000
·
Dominique Mazier
, Josiane Nitcheu
, et al.
·
Parasite Immunology
·
62
Contrasting Timing of Virological Relapse After Discontinuation of Tenofovir or Entecavir in Hepatitis B e Antigen–Negative Patients
2018
·
Christoph Höner zu Siederdissen
, Aric Josun Hui
, et al.
·
The Journal of Infectious Diseases
·
56
Obefazimod in patients with moderate-to-severely active ulcerative colitis: efficacy and safety analysis from the 96-week open-label maintenance phase 2b study
2025
·
Severine Vermeire
, Josianne Nitcheu
, et al.
·
Journal of Crohn s and Colitis
·
26
PDF
OP21 ABX464 is safe and efficacious in a proof-of-concept study in ulcerative colitis patients
2019
·
S Vermeire
, X Hébuterne
, et al.
·
Journal of Crohn s and Colitis
·
15
Therapeutic vaccination of chronic hepatitis B patients with ABX203 (NASVAC) to prevent relapse after stopping NUCs: contrasting timing rebound between tenofovir and entecavir
2017
·
H. Wedemeyer
, A.J. Hui
, et al.
·
Journal of Hepatology
·
13
Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models
2022
·
Didier Scherrer
, Noel Barrett
, et al.
·
Molecular Cancer Therapeutics
·
6
PDF
P001 Obefazimod upregulates miR-124 and downregulates the expression of some cytokines in blood and rectal biopsies of patients with moderate-to-severe ulcerative colitis.
2023
·
J Santo
, P Gineste
, et al.
·
Journal of Crohn s and Colitis
·
3
1007 – Abx464 is Safe and Efficacious in Proof of Concept Study in Ulcerative Colitis Patients
2019
·
Severine Vermeire
, Xavier Hebuterne
, et al.
·
Gastroenterology
·
2
S9 Efficacy and Safety of Obefazimod in Patients With Ulcerative Colitis at Week 48 of an Open-Label Maintenance Study Among Clinical Nonresponses at Week 8 of the Phase 2b Induction Trial
2024
·
Bruce E. Sands
, Laurent Peyrin-Biroulet
, et al.
·
The American Journal of Gastroenterology
·
1
S1097 Correlation of miR-124 Upregulation and PK Parameters in Blood of Patients With Moderate-to-Severe Ulcerative Colitis Receiving Obefazimod for 16 Weeks
2023
·
Julien Santo
, Aurélien Flatres
, et al.
·
The American Journal of Gastroenterology
·
1
S2 Impact of Obefazimod Induction Therapy on Histologic and Combined Histologic and Endoscopic Outcomes in Patients With Moderately to Severely Active Ulcerative Colitis: Week 8 Results from the Phase 2b Induction Trial
2024
·
Laurent Peyrin-Biroulet
, Bruce E. Sands
, et al.
·
The American Journal of Gastroenterology
S52 Corticosteroid-Free Efficacy and Safety of Ulcerative Colitis Patients Receiving Once-Daily Obefazimod in an Open-Label, 96-Week Maintenance Study Among Patients Who Were Receiving Concomitant Corticosteroids at Induction Baseline
2024
·
Severine Vermeire
, Laurent Peyrin-Biroulet
, et al.
·
The American Journal of Gastroenterology
S1095 Obefazimod in Patients With Moderate-to-Severe Ulcerative Colitis: Efficacy and Safety Analysis From the 96-Week Open-Label Maintenance Phase 2b Study
2023
·
Séverine Vermeire
, Josianne Nitcheu
, et al.
·
The American Journal of Gastroenterology
S1096 Long-Term Upregulation of miR-124 in Blood and Rectal Biopsies of Patients With Moderate-to-Severe Ulcerative Colitis Receiving Obefazimod 50mg Daily for 96 Weeks
2023
·
Julien Santo
, Aurélien Flatres
, et al.
·
The American Journal of Gastroenterology
Ep148 Obefazimod Upregulates Mir-124 and Downregulates the Expression of Some Cytokines in Blood and Rectal Biopsies of Patients With Moderate-to-severe Ulcerative Colitis
2023
·
Julien Santo
, Paul Gineste
, et al.
·
Gastroenterology
PDF
Supplementary Figure from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models
2023
·
Didier Scherrer
, Noel Barrett
, et al.
Supplementary Data from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models
2023
·
Didier Scherrer
, Noel Barrett
, et al.
Supplementary Figure from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models
2023
·
Didier Scherrer
, Noel Barrett
, et al.
Supplementary Figure from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models
2023
·
Didier Scherrer
, Noel Barrett
, et al.
Data from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models
2023
·
Didier Scherrer
, Noel Barrett
, et al.
Data from Demonstration of the Antitumor Activity of the iNKT Agonist ABX196, a Novel Enhancer of Cancer Immunotherapy, in Melanoma and Hepatocarcinoma Mouse Models
2023
·
Didier Scherrer
, Noel Barrett
, et al.
Preclinical and Clinical Development of Synthetic iNKT-Cell Glycolipid Agonists as Vaccine Adjuvants
2012
·
Josianne Nitcheu
, Sandrine Crabe
, et al.
·
Springer eBooks
Show more works
View as search
Works count:
27
Citation count:
682
H-index:
8
I10-index:
8
Year
Topic
Type
